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ABSTRACT: Multidrug resistance (MDR) remains one of the biggest obstacles
for effective cancer therapy. Currently there are only few methods that are available
clinically that are used to bypass MDR with very limited success. In this review we
describe how MDR can be overcome by a simple yet effective approach of using
amphiphilic block copolymers. Triblock copolymers of poly(ethylene oxide)
(PEO) and poly(propylene oxide) (PPO), arranged in a triblock structure PEO-
PPO-PEO, Pluronics or “poloxamers”, raised a considerable interest in the drug
delivery field. Previous studies demonstrated that Pluronics sensitize MDR cancer
cells resulting in increased cytotoxic activity of Dox, paclitaxel, and other drugs by
2−3 orders of magnitude. Pluronics can also prevent the development of MDR in
vitro and in vivo. Additionally, promising results of clinical studies of Dox/Pluronic
formulation reinforced the need to ascertain a thorough understanding of Pluronic
effects in tumors. These effects are extremely comprehensive and appear on the
level of plasma membranes, mitochondria, and regulation of gene expression selectively in MDR cancer cells. Moreover, it has
been demonstrated recently that Pluronics can effectively deplete tumorigenic intrinsically drug-resistant cancer stem cells
(CSC). Interestingly, sensitization of MDR and inhibition of drug efflux transporters is not specific or selective to Pluronics.
Other amphiphilic polymers have shown similar activities in various experimental models. This review summarizes recent
advances of understanding the Pluronic effects in sensitization and prevention of MDR.
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1. INTRODUCTION
Chemotherapy remains the main treatment option for most
cancers despite of its limitations, such as systemic toxicity,
severe side effects, and limited efficacy. The major reason for
chemotherapy failure is poor delivery of drug to cancer cells
and/or intracellular targets. There are a number of barriers that
have to be overcome for successful treatment, and multidrug
resistance (MDR) is one of them. Tumors of different origin
have different susceptibility to chemotherapy, and frequently
cancers are intrinsically resistant. On the other hand, even
though many primary tumors and metastatic lesions, for
example breast, ovarian, and small cell lung carcinomas initially
respond well to the chemotherapeutic treatment, cancers often
relapse and develop drug resistance. Moreover, cancer cells
simultaneously acquire resistance not only to the drug the
patient was treated with but also to the broad spectrum of
drugs that are structurally and functionally unrelated to each
other. Initially MDR was attributed to the expression of drug
efflux transporters on the cell membrane that actively pump the
drugs out of the cells.1 Now it is generally recognized that
MDR is a complex phenomenon and usually is governed by
one or more of the following mechanisms: (1) active drug
removal by drug efflux transporters of the ATP-binding cassette
(ABC) superfamily, such as P-glycoprotein (Pgp, ABCB1),
multidrug resistance-associated protein 1 (MRP1, ABCC1),
and breast cancer resistance protein (BCRP, ABCG2); (2) loss
of cell surface receptors or drug transporters or alterations in
membrane lipid composition that limit diffusion of the drug
into the cells; (3) compartmentalization of the drug in cellular
vesicles; (4) altered/increased drug targets; (5) increased drug
metabolism; (6) alterations in cell cycle; (7) active damage
repair; and (8) inhibition of apoptosis (Figure 1).
Despite much effort contributed to overcoming MDR, the
success is still very limited in clinical settings. This effort mainly
centered on the following approaches.2−6 First, the modifica-
tion of treatment regimens by increasing the dose of the
administered drug(s) or using non-cross-resistant drugs.
Second, use of small molecule inhibitors of drug efflux
transporters to increase the drug uptake in MDR tumors.7−9
Third, use of antibodies and antibody fragments to target and
inhibit drug efflux transporters.10−12 Fourth, silencing of the
gene expression of the drug efflux transporters13−15 or
antiapoptotic proteins, such as BCL213,16 using antisense
oligonucleotides, siRNA, or micro RNA. Fifth, use of small
molecules to suppress non-ABC transporter-mediated resist-
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ance.17,18 Finally, use of nanotechnology-based carriers to
bypass drug efflux transporters in MDR cancer cells.2 Of these
approaches the first two were evaluated in clinics. Unfortu-
nately, a simple dose increase has been associated with
increased risks of systemic toxicity and severe side effects,
while finding a proper combination of non-cross-resistant drugs
in many cases is complicated. As far as the use of the Pgp
inhibitors is concerned, the outcomes were often poor, and
many such inhibitors failed due to toxicity or drug metabolism
associated issues.8,9 Moreover, most of the approaches under
development face traditional drug delivery issues, which are
especially severe in the cases of nucleic acid or protein
therapeutics.
Nanotechnology offers several advantages both for the
delivery of the chemotherapeutic agents, allowing them to
bypass drug efflux transporters, and for the delivery of agents
that could inhibit drug resistance mechanisms to increase
efficacy of the chemotherapy. First, it allows improving
pharmacokinetic parameters of administered compounds.
Nanomedicines have longer circulation times and can passively
accumulate in the tumors with leaky vasculature and poor
lymphatic drainage by the enhanced permeability and retention
(EPR) effect.19,20 Attaching specific tumor-targeting antibodies,
antibody fragments, or other targeting moieties (receptor
ligands, peptides, etc.) can result in active targeting of the
nanomedicines to the tumor cells, which can further improve
drug delivery. Second, two or more active compounds can be
incorporated into a single carrier allowing simultaneous delivery
of several cytotoxic drugs for combination therapy and/or a
cytotoxic drug with a MDR modulator, such as small molecule
inhibitor, antibody, or nucleic acid. Third, a nanocarrier can be
designed in such a way that it will release its cargo at the tumor
site in response to specific tumor conditions, such as pH or
presence of particular enzymes, therefore limiting other organs
and tissues to the exposure to free drug and reducing systemic
toxicity. Finally, in contrast to small molecules that mainly
utilize diffusion to penetrate the cells, nanocarriers are taken up
by either “passive” endocytosis or receptor-mediated endocy-
tosis and, therefore, can bypass drug efflux transporters on the
plasma membrane. In the latter case the endocytosis is triggered
by interaction of targeting ligand with its receptor on plasma
membrane, which accelerates the uptake compared to “passive”
endocytosis. If the receptor is predominantly expressed on
cancer cells, in addition to faster uptake this allows selective
targeting of the nanocarrier to cancer cells.
Additionally, polymeric carriers can have a biological activity
of their own. One such example is represented by a class of
copolymers, called Pluronic block copolymers or poloxamers,
that are widely used in various drug delivery systems21−32 and
in tissue engineering.33−36 Pluronics are triblock copolymers of
poly(ethylene oxide) (PEO) and poly(propylene oxide)
(PPO), arranged in PEO-PPO-PEO structure. Depending on
the length of the blocks the hydrophilic−lipophilic balance
(HLB) of the copolymers changes. In the solution Pluronics
spontaneously form micelles above the critical micelle
concentration (CMC). The core of the micelles contains
PPO blocks and allows incorporation of hydrophobic drugs.
Previously thought to be “inert”, Pluronics display a unique set
of biological activities and have been shown to be potent
sensitizers of MDR cancer cells in vitro and in vivo.21,23,37−40
Moreover, Pluronics were shown to prevent the development
of MDR upon selection with an anthracycline antibiotic,
doxorubicin (Dox), both in vitro and in vivo.41,42 We have also
recently demonstrated that Pluronics in combination with Dox
can deplete tumorigenic cell subpopulations and decrease
cancer cells’ tumorigenicity and tumor aggressiveness upon
treatment in vivo.22 In this review we will discuss each of these
mechanisms in more details.
2. REVERSAL OF ABC TRANSPORTER-MEDIATED
RESISTANCE BY PLURONICS
2.1. Structure and Function of ABC Transporters. The
first drug efflux transporter in cancer cells was described by
Juliano and Ling in 1976.1 They have shown that drug-resistant
Chinese hamster ovary cells express a 170 kDa membrane
glycoprotein, now known as P-glycoprotein (Pgp, ABCB1),
that was unique to the drug-resistant cells.1 The cells were
selected for resistance to colchicine and showed cross-resistance
to a wide range of different compounds. The degree of drug
resistance correlated with the amount of Pgp on the cell
surface. Later, in early 1990s a second drug efflux transporter,
called multidrug resistance-associated protein (MRP1 or
ABCC1), was discovered in a drug-resistant lung cancer cell
line.43 Pgp and MRP1 show a partial overlap in substrate
specificity. Normally MRP1 plays a major role in cell
detoxifying mechanism by transport of exogenous and
endogenous compounds conjugated to glutathione (GSH),
which for some substrates is required as a cofactor for MRP1
activity. In contrast, Pgp does not require a cofactor and can
efflux a wide variety of functionally and structurally diverse but
commonly hydrophobic drugs.44 Another important drug efflux
transporter, named breast cancer resistance protein (BCRP,
ABCG2), was identified in 1998 by Doyle et al. in human breast
cancer cell line selected for Dox resistance.45 Its expression is
associated with resistance to number of drugs, such as
mitoxantrone, camptothecins, anthracyclines, etc.46 Pgp,
MRP1, and BCRP belong to the large superfamily of ATP-
binding cassette (ABC) membrane transporters with 48
members of the superfamily that are divided into 7 subgroups
Figure 1. Mechanisms of MDR in cancer cells: (1) active drug efflux
by drug transporters, such as Pgp, MRP, and BCRP; (2) loss of cell
surface receptors and/or drug transporters or alterations in membrane
lipid composition; (3) compartmentalization of the drug in cellular
vesicles; (4) altered/increased drug targets; (5) alterations in cell
cycle; (6) increased drug metabolism/enzymatic inactivation; (7)
active damage repair; and (8) inhibition of apoptosis.
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(A−G). They have conserved structures and ubiquitously
expressed in all forms of living organisms, from bacteria to
humans. Pgp is the most studied ABC transporter (Figure 2). It
is a product of mdr1 gene and can be found in many normal
tissues, like epithelial cells of gastrointestinal tract,47 liver, the
luminal membrane of proximal tubular epithelial cells in
kidney,48,49 cornea,50 and the luminal membrane of the
endothelial cells in the blood−brain barrier.51 Overall, Pgp is
mostly expressed in tissues with barrier functions and its main
role is to protect the organism from toxic compounds. It has a
typical structure for ABC transporters and comprises two trans-
membrane domains (TMDs), each of which has 6 membrane-
spanning α helixes, and two intracellular nucleotide-binding
domains (NBDs), which bind and hydrolyze ATP providing
energy for transmembrane movement of the drugs (Figure 2).
Pgp substrates are mostly hydrophobic (but structurally
unrelated) and partition into a lipid bilayer.52 Among these
substrates are important anticancer drugs including several
anthracyclines (Dox, daunorubicin, mitoxantrone), vincristine,
taxanes, etoposide, teniposide, actinomycin D, and others.
Understanding the mechanism of Pgp function is critical for the
design of novel effective MDR modulators. Several models for
Pgp-mediated drug transport have been proposed.53−56
Recently the crystal structure of mouse Pgp, which has 87%
sequence identity to human Pgp, was described56 (Figure 2).
By analyzing the costructures of Pgp complexes with two
cyclopeptide inhibitors the authors elucidated the mechanism
of drug efflux by Pgp and provided insight into the transporter’s
broad substrate specificity. The drug-binding pocket of Pgp is
localized in the TM domain of the protein. The inward-open
conformation of Pgp allows the substrate access both from
cytoplasm and from the inner leaflet of the membrane but not
from the upper leaflet or extracellular space. The upper part of
the drug-binding pocket contains predominantly hydrophobic
and aromatic amino acid residues, and the lower half of the
chamber has more polar and charged residues. The drug-
binding pocket in Pgp is very large and in inward-facing
conformation is accessible through two portals that are wide
enough to fit hydrophobic drugs and phospholipids and allow
Pgp to “scan” the inner leaflet to select and bind specific lipids
and hydrophobic drugs before transport.56 Overall, the authors
proposed, that Pgp has broad flexibility and can sample widely
open conformations to accommodate large substrates, explain-
ing the broad substrate specificity of the transporter. Usually
the drug enters Pgp’s binding site from the inner leaflet of the
membrane, which stimulates the binding of two molecules of
ATP by NBDs followed by their dimerization. The
dimerization of NBDs causes the major conformational change
in the protein and formation of the outward-facing structure,
open to the extracellular space. The drug is released due to the
change of the affinity of the protein to it or is facilitated by ATP
hydrolysis, which brings the protein back to the initial state.56
2.2. Inhibition of Pgp Activity by Pluronic: Role of
Pluronic−Membrane Interactions. As was mentioned
above, Pluronic block copolymers are potent sensitizers of
MDR cells. The sensitization mechanism is complex and
involves multiple events happening at different levels in the cell.
The polymer−cell interaction starts in the cell membrane,
where drug efflux transporters are localized. Pluronics were
shown to be strong inhibitors of ABC transporters, specifically
Pgp, MRP, and BCRP.39,57−59 They suppress the transporters’
ATPase activity and their interaction with the drug. The
inhibition might be in part due to the alterations of lipid
microenvironment of the transporters by Pluronic. Due to their
amphiphilic structure, Pluronic block copolymers can interact
with cell membrane and change its properties,60 which are
critical for proper function of ABC transporters.
2.2.1. Role of Lipid Microenvironment for Pgp Function.
Membrane structure and composition play a crucial role in cell
physiology, function, and signaling. Plasma membrane is a
heterogeneous structure composed of various domains with
different lipid composition and packing.61 In particular, so-
called “lipid rafts” are compact membrane microdomains
containing predominantly cholesterol and sphingolipids
(mainly sphingomyelin) with long and saturated fatty acids,
that are “floating” in more fluid membrane phase that contains
glycerophospholipids with shorter and unsaturated acyl chains
(Figure 2).62 These domains are resistant to low temperature
solubilization by some detergents, like Triton X100 or Brij 96,
and this is used for their isolation. Depending on the cell line
and the method used for membrane fractionation Pgp can be
found either mostly in detergent-resistant membrane fractions
or distributed between the detergent-resistant and detergent-
soluble fractions.63−66 Furthermore, it was found that Pgp
distribution between different membrane fractions depends on
the transporter’s expression level: the lower the expression of
Pgp is, the greater portion of Pgp is localized in detergent-
resistant cholesterol-rich membrane domains.67 It is well-
known that the function of most membrane proteins is directly
linked to the composition and viscosity of their lipid
microenvironment. Pgp is a lipid flippase68 and requires
interaction with phospholipids for continuous display drug-
Figure 2. Structure and localization of Pgp in plasma membrane. (A)
Pgp is a transmembrane protein with drug-binding pocket localized in
the inner leaflet of the plasma membrane, and two NBD localized in
cytoplasm. Functional Pgp is localized in cholesterol, sphingomyelin,
and GM1 ganglioside-rich membrane microdomains, called lipid rafts,
where it is surrounded by fluid phase of the membrane, containing
unsaturated fatty acids like DPPC. Pgp is pictured in inward-open
(outward closed) conformation ready to bind substrate. The model is
based on X-ray analysis56 and NMR data from protein data bank
(http://www.rcsb.org/). (B) Incorporation of Pluronic into lipid
bilayer disrupts lipid rafts, possibly causing conformational changes in
Pgp, which results in inhibition of Pgp ATPase and transport activities.
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mediated ATPase activity69 and interaction with the substrate.70
Moreover, an increasing number of studies report that Pgp
localization in lipid rafts and precise properties of rafts are
essential for the transporter’s proper function.62 For example
depletion of cholesterol with methyl-β-cyclodextrin in drug-
resistant VLB human T-cell lymphoblastic leukemia cells led to
disassembly of the lipid rafts, redistribution of Pgp from lipid
rafts to other microdomains of plasma membrane, and
inhibition of Pgp transporter activity. On the other hand,
enrichment of membranes with cholesterol also resulted in
inhibition of Pgp function, although the localization of Pgp did
not change compared to control. However, the increase in
cholesterol content changed the lipid raft distribution and
composition, which most likely accounts for the impairment of
the Pgp function.71 It was also shown recently that caveolin-1
overexpression decreases plasma membrane cholesterol levels
(similar to the effect of methyl-β-cyclodextrin that depletes
cholesterol from the membrane) and results in the increase of
membrane fluidity and inhibition of Pgp function in drug-
resistant Hs578T/Dox cells.72 Another study by Barakat et al.
demonstrated that there are two functionally different
populations of Pgp in drug-resistant human CEM lympho-
blastic leukemia cells.63 The first population localized in
detergent-resistant membrane fraction has higher ATPase
activity, which is completely inhibited by orthovanadate and
activated by verapamil. The second population localized in
soluble membrane fractions has lower ATPase activity and is
less sensitive to orthovanadate. Moreover, verapamil, a well-
known Pgp activator, inhibits Pgp ATPase activity in this
second population.63 The authors conclude that interaction of
Pgp with its substrates could be affected by different lipid
microenvironment in soluble membrane fractions, specifically
by lower content of cholesterol compared to the detergent-
resistant membrane fraction.63
2.2.2. Pluronic Interaction with Lipid Membranes. Pluronic
binding to the cell membrane depends on Pluronic hydro-
phobicity and the temperature.73 The binding is driven by
hydrophobic interactions of PPO chain blocks with the fatty
acid residues in the lipid bilayer and by hydrophilic interactions
of PEO chain blocks with the polar groups of the lipids at the
membrane surface. This binding may lead to either membrane
destabilization74 or healing of “injured” membranes.75,76
Pluronics also exhibit ionophoric activity and can facilitate
transmembrane transport of low molecular drugs, accelerate
phospholipid’s flip-flop rate, and decrease membrane micro-
viscosity.73,77,78 Pluronic effects on the membrane transport
depend on the copolymer HLB, concentration, and the
exposure time. For example, hydrophobic Pluronic L61
((EO)4-(PO)30-(EO)4, HLB 3, MW 2000 g/mol, EO =
ethylene oxide; PO = propylene oxide) depending on the
level of its aggregation can act either as a transmembrane carrier
of drug molecules or as an ion channel.78 Specifically, it was
proposed that L61 monomers and dimers can act as the carriers
while L61 oligomers are likely to form the channels.78 On the
other hand hydrophilic Pluronic F68 (Poloxamer 188, (EO)76-
(PO)39-(EO)76, HLB 29, MW 8400 g/mol) with 80% PEO
content effectively restores damaged cell membranes after
electroporation, heat shock, or intense radiation.79−81 Using X-
ray reflection (XR) and grazing-incidence X-ray diffraction
(GIXD) methods in a model Langmuir lipid monolayer of 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-
dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (DPPG),
Wu et al. have shown that F68 interacts with the damaged
membrane areas, but does not affect the ordered membrane
phase, and gets excluded when lipid packing density is
restored.76 Recently it was demonstrated that F68 molecules
do not insert into lipid bilayer nor affect the overall lipid
packaging, however, they facilitate the membrane sealing
activity by diminishing the fluctuation of membrane surface
and hydration of the inner part of the bilayer.82 However, in
another study using giant unilamellar vesicles (GUV) as model
membrane system Wang et al. demonstrated that F68 can
incorporate in the membranes, disrupt their integrity, and act as
a permeabilizer if it is exposed to the membranes for sufficient
time.83
Overall, the interaction of Pluronics with lipid membranes
proceeds in two steps: (1) the absorption at the membrane and
(2) the insertion in the membrane (Figure 3). The first step is
common to all Pluronics and does not depend much on the
copolymer structure. The second step depends strongly on the
hydrophobicity of the copolymer with the more hydrophobic
copolymers being morel likely to insert.83 Extremely hydro-
philic Pluronics absorb on the membrane without penetrating
into the lipid bilayer. Pluronics with longer PPO blocks insert
into the membrane below the polar head groups, loosen the
lipid packaging, and, therefore, act as permeabilizers,82 They
can translocate through the membrane (depending on their
HLB). Furthermore, using molecular dynamics simulations
Nawaz and coauthors observed that membrane bends upon
insertion of Pluronics.84 They have shown that membrane-
Figure 3. Schematic presentation of interaction of Pluronics with different hydrophobicity with lipid membranes: (1) absorption of Pluronic
molecules on the surface of the membrane, (2) insertion into the lipid bilayer, and (3) translocation through the membrane.
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disruptive activity of Pluronics is due to interaction of
hydrophilic blocks with the polar head groups of the lipid
molecules and depends on the length of the PEO block. Short
PEO blocks drag the polar groups toward the inner part of the
membrane, which results in membrane bending and permeabi-
lization. Pluronics with longer PEO blocks can temporarily
stabilize the local structure of the membrane.
Pluronic copolymers can significantly increase the antitumor
activity of PEGylated liposomal drugs in vivo, specifically
DOXIL by stimulating the drug release from liposomes at the
tumor site.30 One of the main problems of long circulating
liposomal drugs is insufficient release of the active compound at
the tumor site. We have demonstrated that “post-admin-
istration” of Pluronic P85 ((EO)26-(PO)40-(EO)26, HLB 16,
MW 4600 g/mol) 48 h after DOXIL results in Dox release and
redistribution toward tumor bulk along with a marked
improvement of antitumor activity. This effect is time-
dependent as it is essential to allow sufficient time for the
liposomes to accumulate at the tumor site before administering
Pluronic. It is likely that that the enhanced antitumor effect at
least in part is due to facilitated release of Dox from the
liposomes in the tumors induced by Pluronic. Furthermore, in
addition to permeabilization effect on liposomal membranes
the copolymer could also sensitize the MDR cells and deplete
the cancer stem cells (CSCs) (as discussed below).22,29
Another important aspect in Pluronic interactions with lipid
membranes is the dependence of these interactions on the cell
type and the membrane composition. For example, the
membrane microviscosity of murine myeloma SP2/0 cells
significantly decreased after treatment with L61, while the
membrane viscosity in normal mouse splenocytes was less
affected.73 Moreover, Pluronic P105 ((EO)37-(PO)56-(EO)37,
HLB 15, MW 6500 g/mol) was demonstrated to permeabilize
the acidic endosomal vesicles in drug-resistant A2780/ADR
cells, while the vesicles in sensitive cells were less affected.85
These differences may be attributed to differences in membrane
lipid compositions. Several studies have reported lower fluidity
and higher heterogeneity of plasma membrane in MDR cells
compared to sensitive cells.86,87 Drug-resistant cells also contain
smaller amounts of unsaturated fatty acids and have higher
content of esterified cholesterol and triglycerides.88,89 Using
liposomes of different lipid composition and viscosity it was
demonstrated that the L61 effects on lipid flip-flop and
membrane permeability toward Dox increase as the membrane
viscosity increases.90
Pluronics inhibit Pgp and MRP ATPase activities by
decreasing maximum reaction rate (Vmax) and the affinity of
the enzyme to ATP as well as to the substrates such as
vinblastine (expressed as increase in Michaelis constant, Km).
40
Some neutral detergents, such as Tween-20, Nonidet P-40, and
Triton X-100, were also shown to inhibit Pgp ATPase activity
at concentrations that are required for membrane fluidization.91
Overall, alterations in membrane structure and fluidity induced
by various compounds strongly affect Pgp function. Therefore,
it was suggested that inhibition of the transporter’s activity by
Pluronic is at least partly due to the Pluronic-induced changes
in the local membrane environment (Figure 2).
3. EFFECT OF PLURONIC ON CANCER CELLS’
METABOLISM
To further understand the mechanism of Pluronic sensitization
of MDR cancer cells one needs to focus on the events at the
subcellular level, which were characterized in great detail using
P85 as an example.23 This copolymer exhibits evident and
profound selectivity with respect to energy metabolism in MDR
cancer cells. It is rapidly taken up by the cells via a caveolae-
mediated endocytosis pathway92 and colocalizes with mito-
chondria already 15 min after exposure to the cells.38 This
results in a drastic depletion of intracellular ATP levels in MDR
cancer cells, while non-MDR cells require significantly higher
doses of Pluronic to achieve similar depletion. Noteworthy, the
ability to deplete cellular ATP levels strongly correlates with the
chemosensitization properties of the copolymers in MDR
cells.93 The selectivity of Pluronic copolymers toward MDR
phenotype is probably attributable to innate metabolic and
physiological differences between MDR and non-MDR cells. In
contrast to normal cells, that use oxidative phosphorylation for
ATP production, cancer cells mostly rely on glycolysis as an
adaptation to hypoxic conditions in the early stages of tumor
development.94 Drug-resistant cells require more ATP to
support the drug efflux transporter activity and drug
metabolism. Adaptations leading to MDR therefore in part
are associated with changes in energy metabolism to meet new
energy requirements. It was shown that human breast cancer
cells with acquired resistance to Dox exhibit 3-fold higher
glycolysis rate than their sensitive counterparts.95 Another
study by Miccadei et al. found that both respiration and
glycolysis rates are increased in drug-resistant Ehrlich cells,
resulting in almost 50% higher ATP production compared to
the drug sensitive cells.96 It was also shown that MDR cells
have significantly higher activity of the respiratory chain
complexes in mitochondria where nearly 50% of ATP was
produced, compared to only 35% of ATP produced in
mitochondria of sensitive cells. Moreover, it was later
demonstrated that MDR cancer cells have lower mitochondrial
membrane potential, use fatty acids for mitochondrial oxidation
when glucose becomes limited, and have high levels of
expression of uncoupling protein 2 (UCP2), which results in
less efficient ATP synthesis.97 Overall, the compromised
mitochondrial function in MDR cells may be the Achilles’
heel of MDR cells that allows effective and selective inhibition
of ATP production in drug-resistant cells.
When Pluronic reaches mitochondria of MDR cells, it
inhibits complexes I and IV of the respiratory chain and
depletes mitochondrial membrane potential.38 The mechanism
of Pluronic inhibition of respiratory chain complexes’ activities
is not fully understood. In mitochondria Pluronic may undergo
chemical reaction and provide peroxides to respiratory chain. In
other words Pluronic may act as a prooxidant, which were
shown to induce apoptosis in cancer cells.98 Noteworthy, the
effects of Pluronic on Pgp activity, ATP levels, and cytotoxicity
are reversible. Pgp function is restored 1 h after the removal of
Pluronic. At the same time, the amount of cell-bound Pluronic
rapidly decreases. The sensitization effect of Pluronic is
abolished in the same time frame, while it takes about 10 h
to restore ATP levels.38 Interestingly, Pgp expression seems to
be essential for Pluronic effects on respiration and ATP levels.
Inhibition of oxygen consumption as well as ATP depletion by
Pluronic was observed not only in drug-selected resistant cells
but also in cells stably transfected with mdr1 gene, encoding
Pgp.38,39 Inhibition of Pgp with highly specific inhibitor
GF120918 abolished the Pluronic-induced ATP depletion,
while the inhibitor itself did not affect ATP levels in MDR
cells.38
Pluronic effects in MDR cancer cells exhibit remarkably
simple and clear structure−functional relationships.57 The
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studies of the concentration dependence of the Pluronic in
MDR cells effect suggested that these effects are produced
mainly by the copolymer single chains as they leveled up or
decreased above the CMC. Hydrophilic Pluronics with HLB 20
and above have little if any sensitization effect in MDR cells.
Using Pgp expressing brain microvessel endothelial cells
(BMECs) it was demonstrated that such Pluronics do not
decrease membrane microviscosity, do not inhibit Pgp ATPase
activity, practically do not internalize in the cells, and do not
induce ATP depletion.99 Of all other Pluronics with HLB fewer
than 20 the most active in MDR cells are the copolymers with
intermediate lengths of the hydrophobic PPO block from about
30 to about 60 PO units.100 Such copolymers include L61, P85,
and P105 discussed above. These copolymers bind with the cell
membranes, decrease membrane microviscosity, and inhibit
Pgp ATPase activity.99 Moreover, they internalize into cells and
produce ATP depleting effects. The copolymers with shorter
PPO blocks, fewer than 30 PO units, also internalize in cells.
However, they do not decrease membrane microviscosity, do
not inhibit Pgp ATPase, and do not deplete ATP. Presumably,
they are not sufficiently “disruptive” to the membrane
structures to produce all these effects. The copolymers with
longer PPO blocks produce strong effects decreasing
membrane microviscosity and inhibiting Pgp ATPase. But
they do not penetrate inside the cells and do not reach
mitochondria remaining stuck in the cell membranes,
presumably due to their extreme hydrophobicity. Accordingly,
such hydrophobic copolymers do not induce ATP depletion.99
Notably, it was demonstrated that both ATP depletion and
inhibition of Pgp ATPase activity are essential for the
sensitization of Pgp overexpressing cells.39,93 When one of
these factors was excluded, the drug efflux pump remained
functional in both MDR cancer and Pgp-expressing
BMECs.39,93
4. EFFECT OF PLURONIC ON PROAPOPTOTIC
SIGNALING
Oxidative stress is a condition in which the balance between the
production of reactive oxygen species (ROS) by cells and the
ability to detoxify them is impaired. If oxidative stress persists,
the formed peroxides and free radicals will damage all
components of the cell, including membranes, proteins, and
DNA. Accumulation of significant damage, which a cell fails to
repair, will lead to apoptosis. Generally, oxidative stress is
associated with increased production of ROS and/or decreased
ability of the cell to eliminate these species. Glutathione is a
major cellular antioxidant that protects the cells against ROS,
toxins, and drugs. It is a tripeptide that exists in reduced (GSH)
and oxidized (GSSG) states, and normally more than 90% of
cellular glutathione is in a reduced state. An accurate ratio
between GSH and GSSG is important to maintain the
intracellular redox state, with a decrease in GSH/GSSG ratio
indicative of oxidative stress. GSH is also a cofactor of
glutathione S-transferase (GST), the major cellular detoxifying
enzyme. Furthermore, several members of the MRP family of
ABC transporters require GSH for transport activity. Pluronic
was shown to deplete the GSH levels and inhibit the GST
activity in several MDR cell lines.57 Inhibition of the GSH/GST
detoxifying system in turn decreases the MRP-mediated efflux.
The decrease of cellular GSH is also an early sign of apoptosis
induced by oxidative stress, death receptor activation, or
mitochondrial apoptotic signaling.101
One of the major sources of ROS in the cells is electron
transport chain in mitochondria. In normal conditions oxygen
is reduced in mitochondria by cytochrome c oxidase (complex
IV) to produce water. However, a small amount of electrons
passing through the electron transfer chain reduce oxygen to
produce superoxide radical. The main superoxide radical
producing complexes in mitochondria are NADH dehydrogen-
ase (complex I) and cytochrome bc1 complex (complex III). It
is well-known that inhibition of complex I by certain inhibitors
like rotenone, piericidin A, and rolliniastatin increases the ROS
production. As was mentioned above, Pluronic quickly reaches
mitochondria and inhibits complexes I and IV in MDR cells
(Figure 4). Moreover, it stimulates the production of ROS and
release of cytochrome c, which are the early signs of
mitochondrial apoptotic pathway.38 If ROS are not neutralized,
they induce damage of mitochondrial membrane, proteins, and
DNA. This leads to permeabilization of outer mitochondrial
membrane, swelling of mitochondria, and release of proapop-
totic proteins, like cytochrome c, apoptosis inducing factor
(AIF),102 and endonuclease G.103 In cytoplasm cytochrome c
binds to apoptosis protease activating factor (APAF-1) and
forms apoptosome. The apoptosome cleaves and activates the
procaspase-9 and forms caspase 9. The activated caspase 9 in
turn activates the effector caspases, which all together
contribute to the completion of apoptosis. Similar to ATP
depletion and inhibition of respiration, Pluronic induced the
ROS formation and cytochrome c release selectively in MDR
cells, while non-MDR cells did not respond in that manner.38
In addition to induction of ROS production and cytochrome
c release in MDR cells, Pluronic promotes drug-induced
apoptosis. Treatment of MDR cells with Dox/Pluronic P85
formulation significantly enhanced the proapoptotic signaling
compared to the drug alone and inhibited the antiapoptotic
defense mechanisms in vitro.104 Similar effects were observed in
vivo. It was demonstrated that Dox/Pluronic treatment of
Figure 4. Effect of Pluronic on mitochondrial electron transport chain
in MDR cancer cells. Pluronic quickly enters the cells, reaches
mitochondria, and induces mitochondrial membrane depolarization
(1), inhibition of complexes I (2) and IV (3), release of cytochrome c
(4), and ATP depletion (5).
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tumor-bearing mice significantly increased levels of caspases 8
and 9 compared to Dox alone.105
Overall, Pluronic induces early as well as late stages of
proapoptotic signaling in MDR cells in vitro and in vivo.
Inhibition of mitochondria respiratory chain complexes is most
likely the main reason for increased ROS production in MDR
cells after treatment with Pluronic. Additionally, depletion of
major intrinsic cellular antioxidant GSH would increase cell
sensitivity to the ROS. It has been shown that drug-induced
ROS production may be directly linked to their cytotoxic
activity106,107 and that detoxification of free radicals by GSH/
GST is very important in MDR cells to facilitate drug
resistance.108 Therefore, when combined with Dox, Pluronic
not only drastically increases the drug accumulation in the cells
but also promotes the apoptosis in the MDR cells. This in
combination with the Dox effects results in significantly
increased cell death.
5. PLURONICS PREVENT DEVELOPMENT OF MDR
AND SUPPRESS CSCS
The mechanism of development of MDR in cancer remains a
highly debated subject, and most likely there is no uniform
theory that will apply to all cancers.109−114 It is now widely
accepted that CSCs play an important role in cancer
development, metastasis, and development of drug resistance.
CSCs comprise a small cell subpopulation within the tumor
with distinct functional and phenotypical characteristics. First,
CSCs overexpress specific markers. However, these markers
differ from cancer to cancer and to date there is no uniform
marker that can be used to isolate CSCs from every tumor.109
Second, CSCs have unlimited ability to divide and produce cells
of all other phenotypes in the tumor. Third, CSCs are able to
form tumors when transplanted into mice and to form so-called
tumorspheres when grown in anchorage independent con-
ditions. Finally, CSCs are intrinsically drug resistant: they
overexpress drug efflux transporters, such as Pgp and BCRP,
have active antiapoptotic pathways, and spend most of their
time in the G0 nondividing cell cycle state, which makes them
insensitive to cytostatic drugs often used in chemotherapy.115
Therefore, CSCs can avoid classical chemotherapy and
repopulate the tumor, possibly leading to MDR development.
Moreover, there are reports suggesting that CSCs’ phenotype is
dynamic and can be acquired by non-CSCs under certain
conditions.109,110 Overall, successful therapy needs to be
equally efficient in eliminating both bulk tumor cells and CSCs.
In addition to MDR chemosensitization properties, Pluronics
also prevent the development of MDR upon selection with
cytotoxic drugs in vitro and in vivo.41,42 Specifically, in one study
human breast carcinoma MFC7 cells were selected with Dox
for drug resistance in the presence or absence of P85 at
concentration below CMC (0.001 wt %).41 The cells cultured
with Dox/P85 were not able to grow at concentrations of the
drug exceeding just 10 ng/mL. In contrast, cells cultured with
Dox alone eventually developed MDR and could tolerate up to
10,000 ng/mL Dox in the culture media. Further analysis has
shown that cells treated with Dox/P85 did not overexpress Pgp
and, therefore, remained sensitive to the drug. In contrast, cells
exposed to Dox alone exhibited significant overexpression of
Pgp. This developed drug resistance can be resensitized by
Pluronic to the initial level of the drug sensitive cells.
Interestingly, when the cells were selected with lower
concentration of Dox, they were not sensitized by Pluronic,
even though they displayed low levels of Pgp expression and
detectable levels of mdr1 mRNA. Functional analysis of Pgp
activity using accumulation of Pgp substrate (Rhodamine 123)
showed that Pgp in those cells was not or nearly not functional
compared to more resistant cells.41,42 Even though cells
selected with lower concentrations of Dox were not sensitized
with Pluronic, they showed strong ATP depletion in response
to Pluronic treatment.41 Moreover, it was demonstrated that
selection of cells with Dox and Dox/P85 resulted in very
different changes in the gene expression patterns in these cells.
P85 alone, however, had little if any effect on the gene
expression.41 Similar results were observed in P388 murine
leukemia tumor cells selected for Dox resistance with or
without P85 both in vitro and in vivo.42 Overall, this suggests
that simple addition of “inert” polymer excipient to the drug
drastically changes pharmacogenomic responses of cancer cells
to this drug.
However, our understanding of the mechanism behind the
prevention of MDR development by Pluronic and alterations in
gene expression profiles is very limited. In view of CSC theory a
small population of tumor cells is guiding tumor progression,
metastasis, and MDR development. Since CSCs share certain
characteristics of MDR cells, such as overexpression of drug
efflux transporters (Pgp, BCRP) and altered metabolic
pathways,116−118 we proposed that Pluronics can sensitize
CSCs to chemotherapeutic drugs similar to MDR cells. In a
recent study using the same P388 leukemia ascitic tumor model
as before,42 we demonstrated that Dox/Pluronic combination,
SP1049C, comprising mixed micelles of Pluronic F127
((EO)100-(PO)65-(EO)100, HLB 22, MW 12 600 g/mol) and
L61, effectively decreases frequency of tumor initiating cells
and, as a result, suppresses tumorigenicity and tumor
aggressiveness in vivo.22 In agreement with previous findings,
SP1049C also prevented the development of MDR by
inhibition of BCRP overexpression. In contrast to Dox alone,
SP1049C depleted the tumorigenic CD133+ and ALDH+ cell
subpopulations. Furthermore, in vitro pretreatment of ascitic
cells with SP1049C significantly reduced the in vitro colony
forming potential of the cells already at 10 ng/mL Dox, while
Dox alone had the same effect at 10 times higher concentration.
As mentioned above, Dox/Pluronic combination drastically
changes the gene expression profiles in cancer cells compared
to Dox or Pluronic alone upon continuous exposure. In this
work we have shown that DNA methylation patterns also
change drastically upon in vivo treatment of cancer cells with
SP1049C compared to saline control, polymers, or Dox alone.
It is well-known that misregulation of DNA methylation/
demethylation plays an important role in cancer origin,
progression, angiogenesis, metastasis, and MDR develop-
ment.119−122 SP1049C not only induced the strongest
epigenetic changes but also showed very small overlap of
affected genes with other treatment groups. Functional analysis
of affected genes done using ingenuity pathway analysis (IPA)
has shown that the top affected biological functions and
canonical pathways affected by SP1049C treatment relate to
cellular function, growth, and maintenance, as well as regulation
of stem cell differentiation and pluripotency. Altogether, on top
of MDR sensitization, the prevention of MDR development by
Pluronics, depletion of tumorigenic cell subpopulations, and
decrease of tumorigenicity and tumor aggressiveness offer
significant advantages for the development of new formulations
of approved and/or experimental therapeutics.
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6. RECENT EXAMPLES OF PLURONIC-BASED AND
SIMILAR DRUG DELIVERY SYSTEMS
Pluronic copolymers attracted a lot of attention in drug delivery
and tissue engineering applications. Pluronic-based micellar
formulation of Dox, SP1049C, was the first in class polymeric
micelle drug to advance to clinical stage123 and has successfully
completed phase II clinical trial in advanced esophageal cancer
patients.124 In studies in rodent and nonrodent animal models
it has been demonstrated, as well as in patients, that MTD and
pharmacokinetic profiles of Dox alone and SP1049C are very
similar.37 SP1049C did enhance the tumor accumulation of the
drug in tumor bearing mice. Moreover, animal studies using
MDR overexpressing tumors have shown that Pluronic
formulations in vivo exhibit key effects observed in mechanistic
studies in vitro.105 First, noninvasive single photon emission
computed tomography (SPECT) and tumor tissue radioactivity
sampling demonstrated that intravenous coadministration of
Pluronic P85 with a Pgp substrate, 99Tc-sestamibi, greatly
increases the tumor uptake of this substrate in the MDR
tumors. Second, 31P magnetic resonance spectroscopy (31P-
MRS) in live animals and tumor tissue sampling for ATP
suggest that P85 and Dox formulations induce pronounced
ATP depletion in MDR tumors. Finally, these formulations
were also shown to increase tumor apoptosis in vivo by
terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assay and reverse transcription polymerase chain
reaction (RT-PCR) for caspases 8 and 9.
In phase I clinical study of SP1049C in 26 patients,
maximum tolerated dose (MTD) and dose-limiting toxicity
(DLT) were determined as 70 and 90 mg/m2 respectively.
SP1049C also showed slower clearance compared to conven-
tional Dox. In phase II study 21 patients (19 evaluable for
response) with metastatic or locally advanced unresectable
adenocarcinoma of the esophagus and gastroesophageal
junction (GEJ) were treated with 75 mg/m2 SP1049C every
3 weeks until disease progression or unacceptable toxicity. In
this study SP1049C demonstrated prominent single agent
antitumor activity (47% objective response rate in the evaluable
population, 9 partial responders, 10 month median overall
survival, and 6.6 month progression free survival) with toxicity
profile similar to that of Dox at equivalent dose and
administration schedule.
Unique biological activities of Pluronics in addition to their
drug solubilization properties make Pluronics a very attractive
platform for drug delivery. For example, in recent work Chen
and coauthors used mixed micelles of P105 and F127 to
overcome Pgp-mediated MDR to methotrexate (MTX) in vitro
and in vivo.125 This system has shown relatively high drug
loading and pH-dependent drug release, improved pharmaco-
kinetics, biodistribution and antitumor activity in human lung
(A549) and oral epidermoid carcinoma (KBv) MDR xenograft
tumor models, and reduced systemic toxicity (Table 1). The
same group has also used Pluronic P105/F127 mixed micelles
to deliver docetaxel (DTX) to Taxol-resistant non-small cell
lung cancer.126 While in drug sensitive cells the micelles had
similar IC50 to Taxotere, in drug-resistant A549/Taxol cells
they demonstrated 10-fold lower IC50 compared to Taxotere
control (0.059 μg/mL vs to 0.593 μg/mL). In in vivo A549/
Taxol drug-resistant tumor model DTX loaded mixed Pluronic
micelles showed 69.05% tumor inhibition, versus 34.43% for
Taxotere control (Table 1).126
In another work Shen et al. developed novel Pluronic-
polyethylene imine (PEI)/D-α-tocopheryl polyethylene glycol
1000 succinate (TPGS) nanoparticles to overcome paclitaxel
(PTX) drug resistance and codeliver survivin shRNA.127 TPGS
was used to improve micelle stability and drug loading, P85 was
used to form micelles and inhibit GST activity, and PEI was
used to bind shRNA. These complex nanoparticles have shown
a synergistic effect in cytotoxicity experiments in A549/T PTX
resistant cells, but not in parental A549 drug sensitive cells, and
displayed effective antitumor activity in vivo in MDR tumor
model. Furthermore, the authors have shown that GST isolated
from MDR cells was 3.8 times more active than extracted from
sensitive cells and that both P85 and P85−PEI conjugate
effectively inhibited only GST of MDR cells but not of non-
MDR cells. This is an important observation, since GST plays
an important role in PTX metabolism and its inhibition would
increase accumulation of PTX in the cells. Other examples that
use Pluronic MDR reversal properties for overcoming MDR
include poly(caprolactone)-modified Pluronic P105 (P105-CL)
PTX loaded micelles developed by Wang et al.128 to overcome
ovarian cancer PTX drug resistance. These polymers displayed
ATP depletion, inhibition of mitochondrial function, and
membrane fluidization activities, similar to what was reported
before for other Pluronics.57,99 A few years earlier the same
group developed folate-targeted Pluronic micelles for delivery
of PTX and circumvention of MDR.129 The authors have
shown that folate conjugated Pluronic P105 or L101 PTX
loaded micelles better accumulate in MCF7/ADR cells and
have significantly higher efficiency compared to nontargeted
micelles of PTX alone (Table 1).
The biological response-modifying properties are, however,
not unique to Pluronics. A number of other natural and
synthetic polymers have been reported to inhibit drug efflux
transporters.130,131 For example, polymers developed by
Cambon and colleagues with similar architecture to Pluronics,
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but with poly(styrene oxide) (PSO) instead of PPO, also form
micelles which have shown efficient drug loading and pH-
dependent release, as well as Pgp inhibition activity.130
Furthermore, in another study from the same group the
authors evaluated the structure−activity relationships of nearly
30 copolymers with structures similar to Pluronics, but
containing different hydrophobic blocks, including propylene
oxide, lactide, methylene, butylene oxide, valerolactone,
caprolactone, styrene oxide, and glycidyl.132 Many of the
screened copolymers induced increase of Dox accumulation in
the Pgp overexpressing MDR cells, as well as inhibition of Pgp
ATPase activity. Notably, the most active copolymers had
longer hydrophobic chains compared to what is considered
optimal for Pluronics,99 that is, Pluronics with intermediate
length of hydrophobic block and relatively low HLB.
Furthermore, TPGS was also reported to inhibit Pgp.133
TPGS is a common form of vitamin E, and it has been
recognized as a potent enhancer of oral absorption of drugs due
to inhibition of drug efflux transporters. Collnot et al. compared
TPGS with different PEG lengths (200−6000) and have found
that commercial TPGS-1000 is one the most potent analogues
in the series of polymers. Other pharmaceutical excipients,
including some Tweens (PEGylated sorbitanes), Brij (Alkyl-
PEO surfactants), and Myrj (PEO-stearates), also demon-
strated Pgp inhibition, that strongly depends on HLB of the
polymer,134 albeit they generally remain less potent than
Pluronics.
Altogether, there are number of polymers that possess the
advantageous properties of inhibition of drug efflux transporters
and can be used to overcome cancer MDR or to improve oral
drug bioavailability. Pluronics, however, represent the most
studied group of potent polymers with respect to molecular
mechanism of Pgp inhibition and MDR sensitization.
Considering similar activities observed in other groups of
polymers, it is likely that some general patterns of structure−
activity relationships of Pluronics (HLB, architecture, etc.) and
spectrum of biological effects can be extrapolated to other
amphiphilic polymers.
7. CONCLUSIONS
Intrinsic and acquired drug resistance represents the great
obstacle for successful treatment of cancer. Numerous
approaches have been utilized in attempts to overcome drug
resistance with limited success. In this review we have discussed
the biological properties of Pluronic block copolymers and
other polymers with similar biological activities, which, in
addition to carrier function, make them an attractive platform
for drug delivery. The MDR chemosensitization activity of
Pluronics (and other surfactants) has been known for a while
now, and the mechanisms have been extensively studied
(Figure 5). However, we are still far from complete
understanding of how exactly Pluronics interact with MDR
cells and why these effects are specific to MDR phenotype.
Recent studies have shown that combination of chemo-
therapeutic drug (Dox) with Pluronic effectively depletes
tumorigenic cell subpopulation and decreases tumorigenicity
and tumor aggressiveness.22 This finding being so simple by
nature drastically changes the whole concept from Pluronics
being just another MDR modulator to a class of agents that
might help to combat cancer at its root by killing CSCs. On the
other hand, we now have even more questions regarding the
mechanism of action of Pluronic than we had before. We
believe that thorough understanding of these mechanisms will
allow better design of Pluronic (and similar polymers)-based
drug delivery systems for effective cancer therapy.
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